查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1618746

下一代乳癌诊断和筛检市场：按产品、诊断技术、筛检技术、应用和最终用户 - 2025-2030 年全球预测

Next-Generation Breast Cancer Diagnostic & Screening Market by Product, Diagnostic Technology, Screening Technology, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

下一代乳癌诊断与筛检市场2023年估值为228.1亿美元，预计到2024年将达到251.2亿美元，复合年增长率为10.91%，到2030年将达到471.1亿美元，预计将达到1000万美元。

下一代乳癌诊断和筛检市场包括基因组学、蛋白质组学和液态切片等先进技术和方法，旨在改善乳癌的早期检测、诊断和监测。这些创新的需求源于乳癌发病率的增加、对无创技术的需求以及个人化照护的需求。应用范围广泛，包括用于癌症风险评估的基因检测、使用基于人工智慧的影像诊断系统进行早期检测以及治疗效果的即时监测。最终用户主要是医院、诊断实验室、研究机构和个人化医疗公司。根据市场洞察，成长的推动因素包括医疗保健意识的提高、技术进步、政府支持的增加以及向基于价值的护理的转变。扩大人工智慧和机器学习的整合、提供预测分析以及开发可携式、经济高效的诊断工具以覆盖服务不足的人群，存在机会。公司可以透过与高科技公司合作并投资研发来利用这些机会。然而，某些限制因素阻碍了成长，包括高成本、严格的法律规范以及低收入地区的准入有限。也存在资料隐私问题和对高技能专业人员的需求等挑战。多组体学资料的无缝整合、开发负担得起的诊断试剂套件和即时人工智慧分析等领域的创新提供了有希望的成长路径。此外，我们专注于以患者为中心的护理创新，例如家庭诊断解决方案，可以提高我们的竞争力。市场是动态的，其特点是技术快速采用和竞争激烈，从而促进持续创新并需要强有力的适应策略。成功的关键往往在于协作研究、策略伙伴关係以及对监管变化的回应。为公司提供的策略建议包括投资于客户教育和参与、透过透明度建立信任以及优先考虑跨学科合作，以促进理解和对抗乳癌的整体方法。

主要市场统计
基准年[2023] 228.1亿美元
预计年份 [2024] 251.2亿美元
预测年份 [2030] 471.1亿美元
复合年增长率（%） 10.91%

市场动态：快速发展的下一代乳癌诊断和筛检市场的关键市场洞察

供需的动态交互作用正在改变下一代乳癌诊断和筛检市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球乳癌发生率上升
    • 对疾病早期诊断和治疗的兴趣日益浓厚
    • 政府努力提高人们对乳癌的认识
  • 市场限制因素
    • 昂贵的乳癌诊断和筛检技术
  • 市场机会
    • 下一代乳癌诊断和筛检技术的进展
    • 策略联盟和投资以生产创新的乳癌诊断解决方案
  • 市场挑战
    • 製造复杂性和严格的监管核准流程

波特五力：引领下一代乳癌诊断与筛检市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对下一代乳癌诊断和筛检市场的影响

外部宏观环境因素在塑造下一代乳癌诊断和筛检市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解下一代乳癌诊断和筛检市场的竞争格局

对下一代乳癌诊断和筛检市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵下一代乳癌诊断和筛检供应商的市场绩效评估

FPNV 定位矩阵是评估下一代乳癌诊断和筛检市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，为下一代乳癌诊断和筛检市场制定成功之路

对于旨在加强其在全球市场的影响力的公司来说，对下一代乳癌诊断和筛检市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球乳癌发生率正在上升
      • 疾病早期诊断和治疗的趋势日益明显
      • 政府采取措施提高人们对乳癌的认识
    • 抑制因素
      • 昂贵的乳癌诊断和筛检技术
    • 机会
      • 下一代乳癌诊断和筛检技术的进展
      • 策略联盟和投资以生产创新的乳癌诊断解决方案
    • 任务
      • 製造复杂性和严格的监管核准流程
  • 市场区隔分析
    • 产品：需要先进的乳房摄影系统来改善临床结果
    • 最终用户：扩大乳癌诊断在医院的使用，为更广泛的患者群体提供服务
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章下一代乳癌诊断与筛检市场：副产品

  • 配件
  • 乳房摄影系统
  • 软体和服务

第七章下一代乳癌诊断/筛检市场诊断技术

  • DNA微阵列
  • 实验室晶片和逆转录 PCR
  • 分子诊断
  • 次世代定序
  • 蛋白质微阵列
  • qPCR 和多重检测

第八章下一代乳癌诊断与筛检市场筛检技术

  • 电离乳房摄影技术
    • 3D 乳房断层合成
    • 模拟乳房X光摄影
    • 锥状射束电脑断层扫描 (CBCT)
    • 造影乳房X光摄影（CEM）
    • 全视野数位乳房摄影（FFDM）
    • 分子乳房成像/乳房特异性伽玛成像 (MBI/BSGI)
    • 正电子发射乳房X光摄影（PEM）
    • 正子断层扫描与电脑断层扫描 (PET-CT)
  • 非电离乳房摄影技术
    • 自动全乳超音波(AWBU)
    • 乳腺核磁共振检查
    • 乳房热成像
    • 乳腺超音波检查
    • 电电阻扫描
    • 光学成像

第九章下一代乳癌诊断和筛检市场：按应用分类

  • 癌症筛检
  • 伴同性诊断
  • 风险分析
  • 治疗监测

第10章下一代乳癌诊断与筛检市场：依最终用户分类

  • 乳腺癌护理中心
  • 影像诊断中心
  • 医院/诊所

第十一章北美和南美下一代乳癌诊断和筛检市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区下一代乳癌诊断与筛检市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的下一代乳癌诊断和筛检市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • GE Healthcare 发布 MyBreastAI 套件，帮助临床医师加速乳癌检测
    • Exact Sciences 透过富有远见的合作推动创新的癌症技术和方法
    • 赛默飞世尔科技 (Thermo Fisher Scientific) 与辉瑞 (Pfizer) 合作，扩大国际市场上针对癌症患者的次世代定序检测的区域覆盖范围
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Agendia Inc.
  • Agilent Technologies, Inc.
  • ARTIVION INC.
  • Becton, Dickinson and Company
  • Benitec Biopharma Ltd
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Centogene NV
  • Danaher Corporation
  • Epic Sciences, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AFF0

The Next-Generation Breast Cancer Diagnostic & Screening Market was valued at USD 22.81 billion in 2023, expected to reach USD 25.12 billion in 2024, and is projected to grow at a CAGR of 10.91%, to USD 47.11 billion by 2030.

The scope of the next-generation breast cancer diagnostic and screening market encompasses advanced technologies and methodologies aimed at improving early detection, diagnosis, and monitoring of breast cancer, like genomics, proteomics, and liquid biopsy. Necessity for these innovations stems from increasing breast cancer incidence, demand for non-invasive methods, and the need for personalized care. Applications are broad, including genetic tests for assessing cancer risk, early-stage detection using AI-enhanced imaging systems, and real-time monitoring of treatment efficacy. End-users primarily include hospitals, diagnostic laboratories, research institutes, and personalized medicine companies. Market insights reveal growth driven by rising healthcare awareness, technological advancements, increased governmental support, and a shift towards value-based care. Opportunities are evident in expanding AI and machine learning integrations, offering predictive analytics, and developing portable, cost-effective diagnostic tools to reach underserved populations. For businesses, partnership with tech firms and investing in R&D can capitalize on these opportunities. However, certain limitations impede growth, including high costs, stringent regulatory frameworks, and limited access in low-income regions. Challenges also include data privacy concerns and the need for highly skilled professionals. Innovating in areas such as seamless integration of multi-omics data, developing affordable diagnostic kits, and real-time AI analytics represents promising avenues for growth. Moreover, focus on patient-centered care innovations, such as home-based diagnostic solutions, can provide a competitive edge. The market is dynamic, characterized by rapid technology adoption and high competition, which fosters continuous innovation and necessitates robust adaptive strategies. Success often hinges on collaborations, strategic partnerships, and aligning with regulatory changes. Strategic recommendations for businesses involve investing in customer education and engagement, establishing trust through transparency, and prioritizing cross-disciplinary collaborations to foster a holistic approach to understanding and combating breast cancer.

KEY MARKET STATISTICS
Base Year [2023] USD 22.81 billion
Estimated Year [2024] USD 25.12 billion
Forecast Year [2030] USD 47.11 billion
CAGR (%) 10.91%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next-Generation Breast Cancer Diagnostic & Screening Market

The Next-Generation Breast Cancer Diagnostic & Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of breast cancer worldwide
    • Growing inclination towards early diagnosis and treatment of diseases
    • Government initiatives to raise awareness regarding breast cancer
  • Market Restraints
    • Expensive breast cancer diagnostic & screening technologies
  • Market Opportunities
    • Advancements in next-generation breast cancer diagnostic & screening technologies
    • Strategic alliances and investments to manufacture innovative breast cancer diagnostic solutions
  • Market Challenges
    • Complexity in manufacturing and stringent regulatory approval process

Porter's Five Forces: A Strategic Tool for Navigating the Next-Generation Breast Cancer Diagnostic & Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next-Generation Breast Cancer Diagnostic & Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next-Generation Breast Cancer Diagnostic & Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next-Generation Breast Cancer Diagnostic & Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next-Generation Breast Cancer Diagnostic & Screening Market

A detailed market share analysis in the Next-Generation Breast Cancer Diagnostic & Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next-Generation Breast Cancer Diagnostic & Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next-Generation Breast Cancer Diagnostic & Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Next-Generation Breast Cancer Diagnostic & Screening Market

A strategic analysis of the Next-Generation Breast Cancer Diagnostic & Screening Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Breast Cancer Diagnostic & Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agendia Inc., Agilent Technologies, Inc., ARTIVION INC., Becton, Dickinson and Company, Benitec Biopharma Ltd, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Invivoscribe, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG, Pfizer Inc., QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Breast Cancer Diagnostic & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Accessories, Breast Imaging Systems, and Software & Services.
  • Based on Diagnostic Technology, market is studied across DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics, Next Generation Sequencing, Protein Microarrays, and qPCR & Multiplexing.
  • Based on Screening Technology, market is studied across Ionizing Breast Imaging Technologies and Non-ionizing Breast Imaging Technologies. The Ionizing Breast Imaging Technologies is further studied across 3D Breast Tomosynthesis, Analog Mammography, Cone-Beam Computed Tomography (CBCT), Contrast-Enhanced Mammography (CEM), Full-Field Digital Mammography (FFDM), Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI), Positron Emission Mammography (PEM), and Positron Emission Tomography and Computed Tomography (PET-CT). The Non-ionizing Breast Imaging Technologies is further studied across Automated Whole-Breast Ultrasound (AWBU), Breast MRI, Breast Thermography, Breast Ultrasound, Electric Impedance Tomography, and Optical Imaging.
  • Based on Application, market is studied across Cancer Screening, Companion Diagnostics, Risk Analysis, and Therapeutic Monitoring.
  • Based on End User, market is studied across Breast Care Centers, Diagnostic Imaging Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of breast cancer worldwide
      • 5.1.1.2. Growing inclination towards early diagnosis and treatment of diseases
      • 5.1.1.3. Government initiatives to raise awareness regarding breast cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive breast cancer diagnostic & screening technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in next-generation breast cancer diagnostic & screening technologies
      • 5.1.3.2. Strategic alliances and investments to manufacture innovative breast cancer diagnostic solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in manufacturing and stringent regulatory approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Need for advanced breast imaging systems for enhanced clinical outcomes
    • 5.2.2. End User: Expanding use of breast cancer diagnostics in hospitals to cater to a wider patient population
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Next-Generation Breast Cancer Diagnostic & Screening Market, by Product

  • 6.1. Introduction
  • 6.2. Accessories
  • 6.3. Breast Imaging Systems
  • 6.4. Software & Services

7. Next-Generation Breast Cancer Diagnostic & Screening Market, by Diagnostic Technology

  • 7.1. Introduction
  • 7.2. DNA Microarrays
  • 7.3. Lab-on-a-Chip & Reverse Transcriptase-PCR
  • 7.4. Molecular Diagnostics
  • 7.5. Next Generation Sequencing
  • 7.6. Protein Microarrays
  • 7.7. qPCR & Multiplexing

8. Next-Generation Breast Cancer Diagnostic & Screening Market, by Screening Technology

  • 8.1. Introduction
  • 8.2. Ionizing Breast Imaging Technologies
    • 8.2.1. 3D Breast Tomosynthesis
    • 8.2.2. Analog Mammography
    • 8.2.3. Cone-Beam Computed Tomography (CBCT)
    • 8.2.4. Contrast-Enhanced Mammography (CEM)
    • 8.2.5. Full-Field Digital Mammography (FFDM)
    • 8.2.6. Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI)
    • 8.2.7. Positron Emission Mammography (PEM)
    • 8.2.8. Positron Emission Tomography and Computed Tomography (PET-CT)
  • 8.3. Non-ionizing Breast Imaging Technologies
    • 8.3.1. Automated Whole-Breast Ultrasound (AWBU)
    • 8.3.2. Breast MRI
    • 8.3.3. Breast Thermography
    • 8.3.4. Breast Ultrasound
    • 8.3.5. Electric Impedance Tomography
    • 8.3.6. Optical Imaging

9. Next-Generation Breast Cancer Diagnostic & Screening Market, by Application

  • 9.1. Introduction
  • 9.2. Cancer Screening
  • 9.3. Companion Diagnostics
  • 9.4. Risk Analysis
  • 9.5. Therapeutic Monitoring

10. Next-Generation Breast Cancer Diagnostic & Screening Market, by End User

  • 10.1. Introduction
  • 10.2. Breast Care Centers
  • 10.3. Diagnostic Imaging Centers
  • 10.4. Hospitals & Clinics

11. Americas Next-Generation Breast Cancer Diagnostic & Screening Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Next-Generation Breast Cancer Diagnostic & Screening Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Next-Generation Breast Cancer Diagnostic & Screening Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. GE HealthCare Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection
    • 14.3.2. Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
    • 14.3.3. Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agendia Inc.
  • 3. Agilent Technologies, Inc.
  • 4. ARTIVION INC.
  • 5. Becton, Dickinson and Company
  • 6. Benitec Biopharma Ltd
  • 7. BGI Genomics Co., Ltd.
  • 8. Bio-Rad Laboratories, Inc.
  • 9. Centogene N.V.
  • 10. Danaher Corporation
  • 11. Epic Sciences, Inc.
  • 12. Exact Sciences Corporation
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fujifilm Holdings Corporation
  • 15. GE HealthCare Technologies, Inc.
  • 16. Hologic, Inc.
  • 17. Illumina, Inc.
  • 18. Invivoscribe, Inc.
  • 19. Koninklijke Philips N.V.
  • 20. Laboratory Corporation of America Holdings
  • 21. Merck & Co., Inc.
  • 22. Myriad Genetics, Inc.
  • 23. Novartis AG
  • 24. Pfizer Inc.
  • 25. QIAGEN N.V.
  • 26. Siemens Healthineers AG
  • 27. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET RESEARCH PROCESS
  • FIGURE 2. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET DYNAMICS
  • TABLE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST IMAGING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY 3D BREAST TOMOSYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CONE-BEAM COMPUTED TOMOGRAPHY (CBCT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CONTRAST-ENHANCED MAMMOGRAPHY (CEM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING/BREAST SPECIFIC GAMMA IMAGING (MBI/BSGI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY POSITRON EMISSION MAMMOGRAPHY (PEM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PET-CT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY AUTOMATED WHOLE-BREAST ULTRASOUND (AWBU), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST THERMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ELECTRIC IMPEDANCE TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 165. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 166. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 172. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 173. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 179. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 180. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 190. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 194. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 195. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 201. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 202. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 205. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 207. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 208. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 209. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 213. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 215. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 216. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 222. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 223. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 229. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 230. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 236. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 237. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. NETHERLANDS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. NETHERLANDS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 20